Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes

Okechi S. Oduori, …, Patrik Rorsman, Susumu Seino


Graphical abstract

Find the latest version:

https://jci.me/140046/pdf
Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes

Okechi S. Oduori,1 Naoya Murao,1 Kenju Shimomura,2 Harumi Takahashi,1 Quan Zhang,3 Haiqiang Dou,4 Shihomi Sakai,1 Kohtarō Minami,1 Belen Chancion,4 Claudia Guida,1 Lakshmi Kothegala,4 Johan Tolö,4 Yuko Maejima,2 Norihide Yokoi,1,5 Yasuhiro Minami,6 Takashi Miki,1 Patrik Rorsman,3,4 and Susumu Seino1

1Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. 2Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan. 3Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 4Metabolic Research Unit, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. 5Laboratory of Animal Breeding and Genetics, Division of Applied Biosciences, Kyoto University Graduate School of Agriculture, Kyoto, Japan. 6Division of Cell Physiology, Kobe University Graduate School of Medicine, Kobe, Japan.

By restoring glucose-regulated insulin secretion, glucagon-like peptide-1–based (GLP-1–based) therapies are becoming increasingly important in diabetes care. Normally, the incretins GLP-1 and glucose-dependent insulino tropic polypeptide (GIP) jointly maintain normal blood glucose levels by stimulation of insulin secretion in pancreatic β cells. However, the reason why only GLP-1–based drugs are effective in improving insulin secretion after presentation of diabetes has not been resolved. ATP-sensitive K⁺ (KATP) channels play a crucial role in linking the systemic metabolic status to β cell electrical activity for insulin secretion. Here, we have shown that persistent membrane depolarization of β cells due to genetic (β cells–specific Kcnj11+/− mice) or pharmacological (long-term exposure to sulfonylureas) inhibition of the KATP channel led to a switch from Gs to Gq in a major amplifying pathway of insulin secretion. The switch determined the relative insulinotropic effectiveness of GLP-1 and GIP, as GLP-1 can activate both Gq and Gs, while GIP only activates Gs. The findings were corroborated in other models of persistent depolarization: a spontaneous diabetic KK-Ay mouse and nondiabetic human and mouse β cells of pancreatic islets chronically treated with high glucose. Thus, a Gs/Gq signaling switch in β cells exposed to chronic hyperglycemia underlies the differential insulinotropic potential of incretins in diabetes.

Introduction

Glucose homeostasis is achieved by tight regulation of insulin secretion from pancreatic β cells in response to various physiological factors, including nutrients and hormonal and neuronal inputs. Of these factors, glucose is the primary initiator of insulin secretion (1, 2). Glucose-induced insulin secretion (GIIS) occurs through a sequence of precisely regulated events in pancreatic β cells. Transport of glucose into β cells and enhanced glucose metabolism increase the ATP/ADP ratio, thereby closing the ATP-sensitive K⁺ (KATP) channels. As KATP channel activity maintains a negative resting membrane potential, closure of the channels causes membrane depolarization and activates voltage-dependent Ca²⁺ channels (VDCCs), thereby leading to insulin granule exocytosis (3–5). The KATP channels thus play a crucial role in linking the β cell’s metabolic status to its electrical activity for the release of insulin (6–8).

GIIS is amplified by hormones and neurotransmitters. Many of these function by activation of the trimeric G proteins Gs and Gq (9), which signal via cAMP and diacylglycerol (DAG)/inositol 1, 4, 5-trisphosphate (IP₃), respectively (10). Among them, the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulino tropic polypeptide (GIP), which are released by enteroendocrine L-cells and K-cells following meal ingestion, are critical for preventing postprandial hyperglycemia by amplifying insulin secretion in a glucose concentration–dependent manner (11–13). Using this glucose-dependent effect, incretin-based drugs such as dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists (GLP-1RAs) have been developed and are increasingly used worldwide for diabetes therapy. GIP and GLP-1 contribute almost equally to the incretin effect in healthy individuals (14). However, GIP-induced insulin secretion (GIPIIS) is lost, while GLP-1-induced insulin secretion (GLP-IIS) is preserved in type 2 diabetes (T2D), accounting for the unique therapeutic utility of GLP-1–based treatments (15–20). A number of studies using animal models have suggested that downregulation of the GIP receptor in β cells explains the ineffectiveness of GIP action in insulin secretion in the diabetic state (21–24). However, downregulation of the GLP-1 receptor (GLP-1R) has also been reported in T2D, yet GLP-1 retains its insulino tropic potential (21, 23).

β cell KATP channels comprise 2 subunits: the pore-forming subunit Kir6.2 (encoded by Kcnj11), a member of the inwardly rectifying K⁺ channel family, and the regulatory subunit sulfonylurea receptor 1 (SUR1, encoded by Abcc8), a member of the ATP-binding cassette transporter superfamily (8, 25, 26). Loss-of-function mutations and activating mutations of the β cell KATP channel are
known to cause congenital hyperinsulinism and neonatal diabetes, respectively (7, 27, 28). Global knockout (KO) of Kcnj11 in mice (gKcnj11 Δ/Δ mice) results in lack of GIIS both in vivo and in vitro, but these mice show only slight glucose intolerance due to increased insulin sensitivity from enhanced glucose uptake in skeletal muscles (29, 30). We found that GLP-1IIS from perfused pancreas was partially retained in these mice, while GIP-IIS was severely diminished. Whether or not the differential responsiveness of β cells in gKcnj11 Δ/Δ mice to GLP-1 and GIP is secondary to altered paracrine effects of glucagon secreted from α cells and/or somatostatin secreted from δ cells due to the absence of K<sub>ATP</sub> channels in these cells could not be investigated (31).

We generated β cell–specific Kcnj11–KO mice (βKcnj11 Δ/Δ mice) to enable clarification of the direct role of the β cell K<sub>ATP</sub> channel in insulin secretion and glucose homeostasis. These mice exhibit severe glucose intolerance and impaired GIIS, defects that can be corrected by GLP-1, but not by GIP, indicating that the βKcnj11 Δ/Δ mouse is a useful model for studying the mechanisms underlying the differential effects of GLP-1 and GIP in insulin secretion in diabetes. In addition to studying βKcnj11 Δ/Δ mice, we examined various in vivo and ex vivo models that mimic the inactive state of K<sub>ATP</sub> channels in β cells. We show that persistent depolarization induces a switch from Gs to Gq signaling in β cells in these models and that similar changes are induced in human islets by conditions emulating diabetes. We propose that this switch accounts for the clinical observation that GLP-1 but not GIP is effective in T2D.

**Results**

**Specific deletion of the Kcnj11 gene in β cells (βKcnj11 Δ/Δ) severely impairs glucose tolerance and GIIS in mice.** β cell–specific Kcnj11–KO (βKcnj11 Δ/Δ) mice were generated by crossing Kcnj11 floxed mice with RIP-Cre mice (32) (Supplemental Figure 1A). Cre-negative (Kcnj11<sup>fl/fl</sup>) mice served as littermate controls. A 90% reduction of Kcnj11 mRNA expression was observed in islets isolated from βKcnj11 Δ/Δ mice as compared with control islets, with no difference in the expression of Abcc8 (SUR1), the regulatory subunit of the K<sub>ATP</sub> channel (8, 26) (Supplemental Figure 1B); residual expression of Kcnj11 reflects the presence of K<sub>ATP</sub> channels in non-β cells (α- and δ-cells) in the islets. We compared the expression of Kcnj11 in the heart, skeletal muscles, and brain, tissues reported to express Kcnj11 (7), and found no difference between βKcnj11 Δ/Δ and control Kcnj11<sup>fl/fl</sup> mice (Supplemental Figure 1B). βKcnj11 Δ/Δ mice exhibited no gross abnormalities. Morphological analysis of the islets revealed α cells intermingled with β cells (Supplemental Figure 1C), similar to what is observed in gKcnj11 Δ/Δ mice (29). Insulin content did not differ between control and βKcnj11 Δ/Δ islets (Supplemental Figure 1D). To confirm Kir6.2 deletion functionally, we performed whole-cell K<sub>ATP</sub> current recordings in primary β cells isolated from control and βKcnj11 Δ/Δ mouse islets. The measurements were performed in the standard whole-cell configuration, which involves intracellular dialysis with the medium in the recording pipette. In control cells, wash-in of ATP-free medium resulted in the development of K<sup>+</sup> conductance that could be monitored by 10 mV hyper- or depolarizing pulses from a holding potential of ~70 mV. This current was abolished by tolbutamide, an antidiabetic sulfonylurea that inhibits K<sub>ATP</sub> channel activity. In contrast, such a tolbutamide-sensitive increase in K<sup>+</sup> currents was not detected in βKcnj11 Δ/Δ β cells when dialyzed with ATP-free medium, confirming the absence of functional K<sub>ATP</sub> channels (Figure 1A). In control cells, resting K<sub>ATP</sub> conductance after washout of intracellular ATP was 3.8 nS/pF, which was reduced by 90% in the presence of 100 μM tolbutamide (Figure 1A). In βKcnj11 Δ/Δ β cells, the conductance was less than 0.1 nS/pF and was not affected by tolbutamide. These differences correlated with changes in membrane potential: in control cells, the membrane potential was ~70 mV, but it was only ~25 mV in Kcnj11 Δ/Δ β cells (Figure 1A).

We then characterized the phenotypic changes consequent to deletion of Kcnj11 in β cells. βKcnj11 Δ/Δ mice exhibited significantly higher fasting blood glucose levels and severe glucose intolerance, as assessed by both oral and i.p. glucose challenge (Figure 1B and Supplemental Figure 1E). Whereas the increase in plasma glucose was associated with an approximately 3-fold increase in plasma insulin in control mice, no such effect was seen in βKcnj11 Δ/Δ mice despite the much higher plasma glucose levels (Figure 1B). Plasma levels of total GLP-1 and GIP before and during oral glucose tolerance test (oGTT) were not affected or tended to be higher in βKcnj11 Δ/Δ mice than those in control mice (Figure 1C). Accordingly, the impaired insulin secretory response to glucose in βKcnj11 Δ/Δ mice could not be attributed to reduced secretion of the incretins.

Tolbutamide (50 mg/kg) was ineffective at lowering blood glucose levels in βKcnj11 Δ/Δ mice (Supplemental Figure 1F). In control mice, tolbutamide (100 μM) strongly but transiently stimulated insulin secretion in perfused pancreases (Supplemental Figure 1G). In perfused pancreases of βKcnj11 Δ/Δ mice, basal insulin secretion (at 2.8 mM glucose) was significantly elevated, but tolbutamide (100 μM) was without stimulatory effect, consistent with the absence of functional K<sub>ATP</sub> channels in the β cells. In fact, tolbutamide showed an inhibitory effect in βKcnj11 Δ/Δ mice, possibly reflecting the paracrine effects of tolbutamide-induced stimulation of somatostatin secretion and inhibition of glucagon secretion (33–35). Increasing the glucose concentration from 2.8 to 16.7 mM led to a biphasic stimulation of insulin secretion in pancreases of control mice, an effect that was greatly diminished and delayed in βKcnj11 Δ/Δ mice, while basal insulin secretion (at 2.8 mM glucose) was significantly elevated (Figure 1D). We also determined the glucose dependence of GIIS by static incubations of isolated islets (Figure 1E). Glucose produced a concentration-dependent stimulation of insulin secretion in control islets at glucose concentrations of more than 5.6 mM. Insulin secretion from the islets of βKcnj11 Δ/Δ mice was significantly elevated even at 0.5 mM glucose, and increasing glucose concentrations stimulated insulin secretion to some degree, with maximal response much lower than that of control mice (Figure 1E): a “crossover” was observed at approximately 12 mM glucose explaining why βKcnj11 Δ/Δ mice are glucose intolerant. There was no difference in glucagon secretion between the islets isolated from βKcnj11 Δ/Δ mice and those from control mice (Supplemental Figure 1H). These results indicate that β cell K<sub>ATP</sub> channels are essential for maintaining normal blood glucose levels, GIIS, and sulfonylurea-induced insulin secretion.

GLP-1– but not GIP-based treatment restores glucose tolerance and insulin secretion in βKcnj11 Δ/Δ mice. Incretin-based antidiabetic drugs such as DPP-4 inhibitors and GLP-IRAs act by amplifying insulin secretion in patients with T2D (15, 19). We therefore investigated whether incretin-based treatments are effective in βKcnj11 Δ/Δ mice.
The DPP-4 inhibitor sitagliptin (2 mg/kg) restored fasting normoglycemia and glucose tolerance in βKcnj11−/− mice (Figure 2A and Supplemental Figure 2A). Sitagliptin increased plasma levels of active GLP-1 as well as GIP in βKcnj11−/− mice beyond what was observed in control mice (Figure 2B), and improved the glucose-induced increase in plasma insulin (Figure 2C). To determine the relative contribution of each incretin, we used the GLP-1 receptor (GLP-1R) antagonist exendin-9 to block the GLP-1R-mediated component. Exendin-9 (50 μg/kg) abolished the effects of sitagliptin on glucose tolerance and insulin secretion in βKcnj11−/− mice (Figure 2D and Supplemental Figure 2B), indicating that the effect of sitagliptin is due to increased GLP-1 levels. The findings that the GLP-1RA liraglutide (50 μg/kg) improved glucose tolerance as well as fasting blood glucose levels and increased insulin secretion in βKcnj11−/− mice corroborate this conclusion (Figure 2E and Supplemental Figure 2C). Injection i.p. of GLP-1 (100 μg/kg) reduced
fasting blood glucose levels and glucose excursion in βKcnj11–/– mice to levels of control mice during i.p. glucose tolerance test (i.p.GTT) (Supplemental Figure 2D). The finding that this effect was observed during an i.p.GTT enables us to rule out the influence of endogenous incretins, as they would be released only during an oGTT. In contrast, the glucose-lowering effect of GIP (100 μg/kg) during i.p.GTT was markedly diminished in βKcnj11–/– mice (Supplemental Figure 2E).

To directly evaluate the distinct insulinotropic potentials of GLP-1 and GIP in βKcnj11–/– mice, we measured insulin secretion ex vivo using the perfused pancreas technique (Figure 2F). Although the amplification of first-phase insulin secretion by GLP-1 was reduced in βKcnj11–/– mice, second-phase was significantly enhanced, such that the total amount of insulin secretion shown in A (n = 5–10 for each point). (C) Plasma active incretins before and 15 minutes after glucose challenge shown in A (n = 5–10 for each point). (D) Effects of exendin-9 (Ex9) on blood glucose and plasma insulin during oGTT following sitagliptin treatment. Sitagliptin (orally) and exendin-9 (50 μg/kg, i.p.) were administered to mice 120 minutes before glucose challenge (n = 7–12 per group for blood glucose; n = 6–8 for each point for insulin). Vehicle, water. (E) Effects of iraglutide (Lira) on blood glucose and plasma insulin. Iraglutide (50 μg/kg, i.p.) was administered to mice 120 minutes before glucose challenge (n = 7–12 per group for blood glucose; n = 6–8 for each point for insulin). Vehicle, saline. (F) Effects of incretins on insulin secretion from perfused pancreases. Total amount of GLP-1/IGI5 or GIP/IGI5 over a period of 15–30 minutes is expressed as AUC, in inset (n = 4 for both groups). (G) Dose-dependent effects of incretins on insulin secretion from pancreatic islets. Amplifying effects of each incretin at the indicated concentrations (0, 0.05, 0.1, 0.5, and 1 nM) (n = 6–8 for each point). Statistical analyses were performed by 2-way ANOVA followed by Dunnett’s post hoc test (A–D, G) or by 2-tailed Student’s unpaired t test (F). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01.

Figure 2. GLP-1− but not GIP-based treatment restores glucose tolerance and insulin secretion in βKcnj11–/– mice. (A) Effects of sitagliptin (Sitai) on oGTT. Sita (2 mg/kg) was orally administered to mice 45 minutes before glucose challenge (1.5 g/kg) (n = 5–8 mice per group). Veh, vehicle (water). (B) Plasma active incretins before and 15 minutes after glucose challenge shown in A (n = 5–10 for each point). (C) Plasma insulin before and 15 minutes after glucose challenge shown in A (n = 5–10 for each point). (D) Effects of exendin-9 (Ex9) on blood glucose and plasma insulin during oGTT following sitagliptin treatment. Sitagliptin (orally) and exendin-9 (50 μg/kg, i.p.) were administered 45 minutes and 15 minutes, respectively, before glucose challenge (n = 6–10 per group for blood glucose; n = 7–8 for each point for plasma insulin). Vehicle, water. (E) Effects of iraglutide (Lira) on blood glucose and plasma insulin. Iraglutide (50 μg/kg, i.p.) was administered to mice 120 minutes before glucose challenge (n = 7–12 per group for blood glucose; n = 6–8 for each point for insulin). Vehicle, saline. (F) Effects of incretins on insulin secretion from perfused pancreases. Total amount of GLP-1/IGI5 or GIP/IGI5 over a period of 15–30 minutes is expressed as AUC, in inset (n = 4 for both groups). (G) Dose-dependent effects of incretins on insulin secretion from pancreatic islets. Amplifying effects of each incretin at the indicated concentrations (0, 0.05, 0.1, 0.5, and 1 nM) (n = 6–8 for each point). Statistical analyses were performed by 2-way ANOVA followed by Dunnett’s post hoc test (A–D, G) or by 2-tailed Student’s unpaired t test (F). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01.
Figure 3. Gs to Gq switch in Kcnj11−/− β cells accounts for GLP-1 effectiveness in amplification of insulin secretion. (A) Effects of MDL-2330A (MDL) on GLP-1115 and GIP1IS from islets (n = 6–8 for each condition). Similar results were obtained in 2 independent experiments. (B) Effects of YM-254890 (YM) on GLP-1115 and GIP1IS from islets (n = 6–8 for each condition). Similar results were obtained in 4 independent experiments. Carb, carbachol. (C) Effects of YM-254890 on basal insulin secretion from islets (n = 6–8 each condition). Similar results were obtained in 4 independent experiments. (D) Effects of Gq agonists on insulin secretion from islets (n = 6 for each condition). Similar results were obtained in 4 independent experiments. MK, MK-2305. (E) Western blot analysis of phosphoserine PKC substrates in β cell lines. Left: representative blot: lane 1, parental control; lane 2, Kcnj11−/− JCL1. Right: densitometric analysis of the relative abundance of phosphoserine PKC substrates (n = 4 each). Whole cell lysates incubated with 2.8 mM glucose were used. (F) IP1 in Kcnj11−/− JCL1 (n = 7–8). Similar results were obtained in 2 independent experiments. Note that IP1 in parental control was not detected in any condition indicated. (G) Intracellular Ca2+ ([Ca2+]i). Left: effects of GLP-1 on [Ca2+]i, at 2.8 mM glucose. Middle: effects of high (11.1 mM) glucose alone and high glucose plus GLP-1 on [Ca2+]i, in parental control. Right: effects of high glucose alone, high glucose plus GLP-1, and high glucose plus GLP-1 plus YM-254890 in Kcnj11−/− JCL1. Increment of [Ca2+]i above basal level at 2.8 mM glucose (AF340/F380) is shown (n = 6 for each). Statistical analyses were performed by 2-way ANOVA followed by post hoc Tukey’s test (A, D, and F) or Dunnett’s test (C) and by 2-tailed Student’s unpaired t test (B and E). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01.

Collectively, these results indicate that the amplifying pathway in insulin secretion is switched from Gs to Gq signaling in KATP channel–deficient β cells. We also performed whole-islet RNA-Seq, but found no differences in the expressions of G protein signaling–related genes, calcium signaling–related genes, and insulin exocytosis–related genes between βKcnj11WT and βKcnj11−/− islets (Supplemental Table 1). Moreover, since there were no differences in endogenous Gq and Gprotein levels between parental control and Kcnj11−/− βCL1 (Supplemental Figure 3K), the signaling switch in Kcnj11−/− β cells does not result from altered expressions of genes associated with G protein signaling or amount of the G proteins.

GLP-1, but not GIP, directly activates Gq in Kcnj11−/− β cells while neither GLP-1 nor GIP activates Gq in control β cells. To ascertain that GLP-1 directly enhances coupling of GLP-1R and Gq, we used the Gq-specific fluorescence resonance energy transfer (FRET) sensor mNG-Gq-IRESGq-mTq2 (49) (Supplemental Figure 4). We expressed this FRET sensor in parental control (MIN6-K8) and Kcnj11−/− βCL1 to monitor activation of Gq in response to various stimuli. Carbachol (50 μM), a positive control of activation of Gq, clearly induced changes in the FRET response in both parental control and Kcnj11−/− βCL1 (Figure 4A), which were blocked by simultaneous application of 100 nM YM-254890. Given these findings, we conclude that the mNG-Gq-IRESGq-mTq2 expressed in these cells functions as a Gq FRET sensor. We next compared the responses to GLP-1 (1 nM) in parental control and Kcnj11−/− βCL1 cells using mNG-Gq-IRESGq-mTq2. In Kcnj11−/− βCL1, but not in parental control, GLP-1 induced a FRET response that was comparable in magnitude to that elicited by carbachol, which was abolished by 100 nM YM-254890 (Figure 4B). In contrast, GIP (1 nM) did not alter the FRET response (Figure 4C). These results indicate that GLP-1, but not GIP, directly activates Gq in KATP channel–deficient β cells and that neither of them activates Gq in normal β cells.

Enhanced Gq signaling and reduced Gs signaling are commonly found in various models of persistently depolarized β cells. β Cells of βKcnj11−/− mice are permanently depolarized (Figure 1A). It has been shown that membrane potential modulates activation of Gq protein–coupled receptors (GqPCRs) in several cell types, such as neurons and smooth muscle cells (50). We therefore hypothesized that persistent depolarization of β cells caused by metabolic, pharmacological, or genetic inactivation of the KATP channels might enhance Gq signaling in β cells.

We tested this by chronic culture of WT mouse (B6) islets with high glucose (25 mM for 3 days) or the sulfonylurea tolbutamide (500 μM for 5 days) to mimic the conditions in βKcnj11−/− mice. β Cells in islets cultured under high glucose conditions were likewise depolarized when membrane potential was subsequently measured at low glucose (1 mM), a finding similar to that reported previously (51), and spontaneous low-amplitude action potential firing was observed (Figure 5A). The average membrane potential was approximately –37 mV at 1 mM, and increasing glucose concentration to 10 mM did not produce further depolarization (Figure 5B). In islets cultured with 5.5 mM glucose, β cells responded to high glucose (10 mM) with increased membrane depolarization and generation of large-amplitude action potentials (Figure 5A). The average membrane potential of β cells measured at 1 mM glucose was approximately –66 mV, which increased to approximately –48 mV in the presence of 10 mM glucose (Figure 5B). Basal insulin secretion (at 2.8 mM glucose) was elevated in the high glucose–cultured islets compared with islets cultured with 5.5 mM glucose. While GLP-11IS was retained in the high glucose–cultured islets, GIP1IS was diminished (Figure 5C).

Similar results were obtained by sulfonylurea treatment of WT islets (Supplemental Figure 5A). In islets treated chronically with
mM) with increased membrane depolarization and firing of large-amplitude action potentials (Figure 5D). The average membrane potential of KKβ cells exposed to 1 mM glucose was approximately –80 mV, and the membrane potential was increased to approximately –65 mV when the β cells were exposed to 10 mM glucose (Figure 5E).

β Cells from KK-Ay mice exposed to 1 mM glucose were strongly depolarized compared with those from KK mice (approximately –30 mV), and there was no further depolarization by increasing glucose to 10 mM with no clear action potential firing (Figure 5, D and E). We then examined insulin secretory properties of KK and KK-Ay mice (Figure 5F). In isolated islets from KK mice, GIIS, GLP-1IIS, and GIPIIS were similar to those observed in Kcnj11fl/fl mice. KK-Ay mice exhibited higher basal insulin secretion than that in KK mice. Increasing glucose from 2.8 to 11.1 mM stimulated insulin secretion in KK-Ay mice, but the effect of high glucose was limited to 50% stimulation, much less than the 500% tolbutamide (500 µM, 5 days) the resting membrane potential of β cells subsequently measured at 1 mM glucose in the absence of tolbutamide was elevated compared with vehicle-treated islets (approximately –30 mV vs. approximately –70 mV). In these islets, basal insulin secretion was also elevated. No insulin responses to high glucose, enhanced GLP-1IIS, and loss of GIPIIS were observed. None of these effects were seen following short-term treatment with tolbutamide (Supplemental Figure 5B).

Although the βKcnj11/– mouse shows similar characteristics to those of T2D, the mouse generated by β cell–specific ablation of Kcnj11 with gene technology is a very unique diabetes model. We therefore extended our observations to the KK-Ay mouse, a mouse model of spontaneous obese T2D, which is a product of cross-breeding between obese KK and lethal agouti yellow (Ay) mice and carries heterozygous mutation of the agouti gene (52). β Cells from nondiabetic control KK mice responded to high glucose (10 mM) with increased membrane depolarization and firing of large-amplitude action potentials (Figure 5D). The average membrane potential of KK β cells exposed to 1 mM glucose was approximately –80 mV, and the membrane potential was increased to approximately –65 mV when the β cells were exposed to 10 mM glucose (Figure 5E). β Cells from KK-Ay mice exposed to 1 mM glucose were strongly depolarized compared with those from KK mice (approximately –30 mV), and there was no further depolarization by increasing glucose to 10 mM with no clear action potential firing (Figure 5, D and E). We then examined insulin secretory properties of KK and KK-Ay mice (Figure 5F). In isolated islets from KK mice, GIIS, GLP-1IIS, and GIPIIS were similar to those observed in Kcnj11/– mice. KK-Ay mice exhibited higher basal insulin secretion than that in KK mice. Increasing glucose from 2.8 to 11.1 mM stimulated insulin secretion in KK-Ay mice, but the effect of high glucose was limited to 50% stimulation, much less than the 500%
observed in KK mice. It should be noted, however, that a membrane potential of ~30 mV is sufficient to activate VDCCs in β cells, explaining the stimulation of insulin secretion despite the apparent lack of regenerative electrical activity in KK-Ay islets. While GLP-1 amplified GIIS, GIP was ineffective in KK-Ay islets. The amplifying effect of GLP-1 on GIIS was abolished by YM-254890 (100 nM) in KK-Ay islets, but this compound had no effect in KK islets. Overall, data from hyperglycemic KK-Ay mice corroborate the findings in βKcnj11−/− islets and WT islets chronically exposed to high glucose or sulfonylurea.

**Chronic treatment of human islets with high glucose stimulates electrical activity of β cells and basal insulin secretion.** We extended these observations to human islets using the high-glucose culture protocol. Human islets were cultured at 5.5 or 16.7 mM glucose for observed in KK mice. It should be noted, however, that a membrane potential of ~30 mV is sufficient to activate VDCCs in β cells, explaining the stimulation of insulin secretion despite the apparent lack of regenerative electrical activity in KK-Ay islets. While GLP-1 amplified GIIS, GIP was ineffective in KK-Ay islets. The amplifying effect of GLP-1 on GIIS was abolished by YM-254890 (100 nM) in KK-Ay islets, but this compound had no effect in KK islets. Overall, data from hyperglycemic KK-Ay mice corroborate the findings in βKcnj11−/− islets and WT islets chronically exposed to high glucose or sulfonylurea.

**Chronic treatment of human islets with high glucose stimulates electrical activity of β cells and basal insulin secretion.** We extended these observations to human islets using the high-glucose culture protocol. Human islets were cultured at 5.5 or 16.7 mM glucose for
cultured at high glucose (16.7 mM) for 3 days, spontaneous activity at 1 mM glucose was much higher (in the experiment shown, nearly 100% of cells were active) than in those cultured at 5.5 mM, and increasing glucose to 11 mM exerted no further stimulatory effect. While some of these cells may represent non-β cells, the activity of β cells at low glucose is clearly increased in islets cultured at high glucose. The responses shown are representative of 3 islets from each of the 4 donors analyzed. We correlated these effects to insulin secretion (Figure 6C). Islets cultured at 5.5 mM glucose for 3 days responded to elevation of glucose from 2.8 mM to 11.1 mM with an increase in insulin secretion by 125%. In islets cultured at 16.7 mM glucose for 3 days, basal secretion at 2.8 mM glucose was increased by more than 200%, and increasing glucose to 11.1 mM caused only a slight increase in insulin secretion (<30%) that did not reach statistical significance.

The Gq-specific agonist MK-2305 improves glucose tolerance in βKcnj11−/− mice and KK-Ay mice. To determine whether enhanced Gq signaling in β cells contributes to improvement of the diabetic state in vivo, we examined the effect of the Gq-specific agonist MK-2305 (10 mg/kg) on glucose tolerance in βKcnj11−/− mice and KK-Ay mice. Oral administration of MK-2305 to βKcnj11−/− mice before oGTT normalized fasting hyperglycemia and markedly improved glucose tolerance (Figure 6C). In βKcnj11−/− mice, fasting glucose was reduced by 40% at 1 h after the glucose load, and the area under the glucose tolerance curve was reduced by 43% compared with vehicle-treated mice. These effects were not observed in vehicle-treated mice (Figure 6C).

We also monitored [Ca²⁺] in intact human islets (Supplemental Figure 6A). In islets cultured at 5.5 mM glucose, only a small number (10%–15%) of cells showed spontaneous activity at 1 mM glucose and may represent α cells, which are spontaneously active at low glucose (53). The majority of cells were silent at low glucose, but increasing glucose to 11 mM induced increased [Ca²⁺]. In islets cultured at high glucose (16.7 mM) for 3 days, spontaneous activity at 1 mM glucose was much higher (in the experiment shown, nearly 100% of cells were active) than in those cultured at 5.5 mM, and increasing glucose to 11 mM exerted no further stimulatory effect. While some of these cells may represent non-β cells, the activity of β cells at low glucose is clearly increased in islets cultured at high glucose. The responses shown are representative of 3 islets from each of the 4 donors analyzed.

We correlated these effects to insulin secretion (Figure 6C). Islets cultured at 5.5 mM glucose for 3 days responded to elevation of glucose from 2.8 mM to 11.1 mM with an increase in insulin secretion by 125%. In islets cultured at 16.7 mM glucose for 3 days, basal secretion at 2.8 mM glucose was increased by more than 200%, and increasing glucose to 11.1 mM caused only a slight increase in insulin secretion (<30%) that did not reach statistical significance.

The Gq-specific agonist MK-2305 improves glucose tolerance in βKcnj11−/− mice and KK-Ay mice. To determine whether enhanced Gq signaling in β cells contributes to improvement of the diabetic state in vivo, we examined the effect of the Gq-specific agonist MK-2305 (10 mg/kg) on glucose tolerance in βKcnj11−/− mice and KK-Ay mice. Oral administration of MK-2305 to βKcnj11−/− mice before oGTT normalized fasting hyperglycemia and markedly improved glucose tolerance (Figure 6C). In βKcnj11−/− mice, fasting glucose was reduced by 40% at 1 h after the glucose load, and the area under the glucose tolerance curve was reduced by 43% compared with vehicle-treated mice. These effects were not observed in vehicle-treated mice (Figure 6C).
ated amplifying pathways are effective only when GIIS is operative, these pathways are also dependent on the activity of the K ATP channels (1). Although GLP-1IIS and GIPIIIS are both required to maintain blood glucose levels within normal range in healthy subjects, the reason why only GLP-1–based treatments are effective in diabetes remains unknown. We previously reported that gKcnj11–/– mice exhibited only slight glucose intolerance despite a severe defect in GIIS in vivo (29). While the in vitro insulin response to GLP-1 was retained to some extent in gKcnj11–/– islets, that to GIP was markedly reduced (31). These phenotypic changes in gKcnj11–/– mice were due not only to K ATP channel deficiency in the β cells, but also to deficiency of the channels in other cell types/tissues, as the channels are expressed in many cell types, including non-β cells in the islets, skeletal muscle, enteroendocrine cells, heart, and brain (7, 8). For example, increased glucose uptake by skeletal muscles was found in the gKcnj11–/– mice, which may have ameliorated the expected hyperglycemic effect expected from the loss of GIIS (30). We previously reported that gKcnj11–/– mice exhibited only slight glucose intolerance despite a severe defect in GIIS in vivo (29). While the in vitro insulin response to GLP-1 was retained to some extent in gKcnj11–/– islets, that to GIP was markedly reduced (31). These phenotypic changes in gKcnj11–/– mice were due not only to K ATP channel deficiency in the β cells, but also to deficiency of the channels in other cell types/tissues, as the channels are expressed in many cell types, including non-β cells in the islets, skeletal muscle, enteroendocrine cells, heart, and brain (7, 8). For example, increased glucose uptake by skeletal muscles was found in the gKcnj11–/– mice, which may have ameliorated the expected hyperglycemic effect expected from the loss of GIIS (30). Thus, the direct role of β cell K ATP channels in insulin secretion and glucose homeostasis has not yet been clarified. To address this issue, we generated mice lacking K ATP channels specifically in β cells (βKcnj11–/– mice). This mouse model is similar in characteristics to those of human T2D: (a) fasting hyperglycemia and impaired glucose tolerance; (b) impaired insulin response to glucose; (c) retained GLP-1 effect, but diminished GIP effect, on amplification of insulin secretion; and (d) ability of GLP-1 (but not GIP) to restore normal glucose tolerance.

We confirm that both GLP-1 and GIP amplify insulin secretion in β cells of Kcnj11fl/fl mice by mechanisms that involve Gs signaling, whereas only GLP-1 amplifies insulin secretion in β cells of βKcnj11–/– mice. This mouse model is similar in characteristics to those of human T2D: (a) fasting hyperglycemia and impaired glucose tolerance; (b) impaired insulin response to glucose; (c) retained GLP-1 effect, but diminished GIP effect, on amplification of insulin secretion; and (d) ability of GLP-1 (but not GIP) to restore normal glucose tolerance.

We confirm that both GLP-1 and GIP amplify insulin secretion in β cells of Kcnj11fl/fl mice by mechanisms that involve Gs signaling, whereas only GLP-1 amplifies insulin secretion in β cells of βKcnj11–/– mice and then exclusively through Gq signaling. The change in G protein signaling in persistently depolarized β cells may be of therapeutic and pathophysiological significance, as it explains how the insulinotropic effect of GLP-1 is maintained in tolerance in the mice (Figure 7A). Similarly, MK-2305 significantly improved fasting hyperglycemia as well as glucose tolerance and increased plasma insulin levels in KK-Ay mice (Figure 7B). These results suggest that Gq-specific agonists are effective in ameliorating diabetes by amplifying insulin secretion.

Discussion

Insulin secretion from pancreatic β cells is essential for the maintenance of normoglycemia. Impaired insulin secretion is a hallmark of T2D. Modulation of GIIS by neuronal and hormonal inputs is critical for the adjustment of insulin secretion in response to various metabolic demands (9). Among these, the incretins GLP-1 and GIP are particularly important. They prevent postprandial hyperglycemia by amplification of insulin secretion upon meal ingestion (11–17). K ATP channels in β cells transduce changes in blood glucose, via acceleration of glucose metabolism, into electrical activity required for the release of insulin (1, 5). Since the incretin-mediated amplifying pathways are effective only when GIIS is operative, these pathways are also dependent on the activity of the K ATP channels (1). Although GLP-1IIS and GIPIIIS are both required to maintain blood glucose levels within normal range in healthy subjects, the reason why only GLP-1–based treatments are effective in diabetes remains unknown.
T2D, but that of GIP is lost. This is because GLP-1 activates both Gs and Gq in β cells, while GIP activates only Gs. These findings are supported using other experimental paradigms associated with persistent membrane depolarization of β cells due to K\textsubscript{ATP} channel inactivation, such as diabetic/hyperglycemic mice as well as mouse and human pancreatic islets chronically treated with high glucose or sulfonylurea. We also show that the stimulation of insulin secretion by agents that operate through Gq signaling is enhanced in persistently depolarized β cells.

Changes in membrane potential are known to directly modulate activation of GPCRs, especially class A GPCRs (50, 54, 55). Although the mechanisms by which membrane potential modulates GPCRs are not fully understood, recent studies have shown that allosteric effects of Na\textsuperscript{+} on class A GPCRs modulate GPCR activation and GPCR-mediated signaling (54–56). Binding of voltage-driven translocated Na\textsuperscript{+} to the highly conserved aspartic acid residue in transmembrane domain 2 (Asp\textsuperscript{6.53b}) in class A GPCRs, combined with the effects of the Na\textsuperscript{+}-coordinating residues, modulates GPCR agonist binding and activation. In addition, Na\textsuperscript{+}-coordinating residues and Na\textsuperscript{+} itself could also lead to selectivity of distinct GPCR-mediated signaling pathways (so called “signaling bias”), as exhibited by the δ opioid receptor (57). Allosteric modulation of class B GPCRs has also been studied (58), but their modulation by membrane potential remains unknown. A mechanism similar to that in class A GPCRs has recently been proposed for class B GPCRs as well, based on a study of the glugagon receptor as a model (59). In this model, binding of Na\textsuperscript{+} to residues at Asn\textsuperscript{3.43b}, Glu\textsuperscript{6.53b}, and Gln\textsuperscript{7.49b} (60) is thought to be important for allosteric modulation of the glugagon receptor by Na\textsuperscript{+}. Notably, all these residues are conserved in glucagon, GLP-1, and GIP receptors (60). Although allosteric effects of Na\textsuperscript{+} on GLP-1 and GIP receptors are yet to be clarified, it is possible that persistent depolarization of β cells induces signaling bias as well as modulation of the activities of GLP-1R and GIP receptor. In support of this are the findings that modulation of class A GPCR activities by membrane potential differs by depending on the GPCR itself, agonist, and cell type (50). For example, whereas depolarization reduces the activity of the M2 receptor (G\textsubscript{M2,PCR}), it enhances the activity of the M1 receptor (G\textsubscript{M1,PCR}) (61). Given that Na\textsuperscript{+} resident time in the binding site is very short, it seems reasonable that persistent, but not transient, depolarization of β cells leads to a switch from Gs to Gq signaling. Elevated Ca\textsuperscript{2+} level in β cells may also contribute to enhanced downstream signaling of Gq through activation of phospholipase C, as has been reported in insulin-secreting INS-1 cells (62). Further studies are required to elucidate the mechanisms by which membrane potential modulates GLP-1 and GIP receptor activities and their downstream signals.

Based on our findings, we propose the following model to explain differential modulation of insulin secretion by GPCRs (Figure 8). In resting β cells, insulin secretion is low under basal conditions (low glucose and no activation of GPCRs) because of high K\textsubscript{ATP} channel activity (Figure 8A). Under a stimulated state (high glucose, high levels of ligands for GPCRs), K\textsubscript{ATP} channels are closed and the resulting membrane depolarization causes opening of VDCCs and stimulation of insulin secretion. Under this condition, GLP-1 and GIP both activate Gs and increase cAMP production, thereby amplifying insulin secretion through PKA- and Epac2-dependent pathways (63, 64) (Figure 8B). In persistently depolarized β cells (regardless of this being a consequence of genetic, pharmacological, or metabolic intervention leading to reduced K\textsubscript{ATP} channel activity), Gq signaling (i.e., the DAG/PKC pathway and the IP\textsubscript{3}/Ca\textsuperscript{2+} pathway) is enhanced even at basal state. This contributes to further inhibition of the K\textsubscript{ATP} channels (65) and activation of a depolarizing background conductance (41), leading to sustained elevation of [Ca\textsuperscript{2+}]. As a result, basal secretion of insulin is stimulated (Figure 8C), which disables the normal metabolic regulation of insulin secretion. In such persistently depolarized β cells, GLP-1 or other ligands for GqPCRs (such as muscarinic agonist and fatty acids) further enhance Gq signaling and amplify insulin secretion (Figure 8D). Indeed, we have shown that the Gq agonist MK-2305 drastically improves glucose tolerance and insulin secretion in vivo in the KK-Ay mouse, a model of T2D, as well as glucose tolerance in βKcnj11\textsuperscript{−/−} mice (Figure 7A and B). This concept is supported by the finding that the Gq-specific inhibitor YM-254890 reduced basal insulin secretion and restored normal glucose regulation of β cell electrical activity (Figure 3C and Figure 6, A and B). In contrast, the amplifying effect of GIP on insulin secretion is diminished because Gs signaling is suppressed in persistently depolarized β cells. GLP-1Rs can couple to both Gs and Gq in various cell types, including β cells (36, 40, 41), but there is no evidence that GIP receptors can couple to Gq.

Together, these findings explain the differential effects of GLP-1 and GIP in the amplification of insulin secretion in persistently depolarized β cells. Although precise molecular mechanisms remain to be elucidated, it is clear that there is a switch from Gs to Gq signaling in persistently depolarized β cells. Our findings clarify why GLP-1– but not GIP-based therapies are effective in T2D and also provide a mechanism accounting for the increase in basal insulin secretion that is a characteristic feature of the disease (i.e., chronic hyperglycemia leads to reduced K\textsubscript{ATP} channel activity that leads to stimulation of β cell electrical activity, which leads to activation of Gq, thereby resulting in elevated basal insulin secretion).

These findings have immediate therapeutic implications for T2D. Since membrane depolarization resulting from reduced K\textsubscript{ATP} channel activity in hyperglycemia diminishes Gs signaling, normalization of membrane potential of β cells by reactivation of K\textsubscript{ATP} channels could improve GIPIIS through restored Gs signaling. This may explain the beneficial effects of therapeutic interventions that result in reduced plasma glucose, such as calorie restriction (66). In this context, it is noteworthy that the insulinotropic effects of endogenous GIP are reestablished after lowering blood glucose by treatment with insulin (67) or sodium-dependent glucose transporter-2 (SGLT-2) inhibitors (68).

In summary, the present data demonstrate that, while Gs is the primary signal for amplification of GIIS in normal β cells, Gq is the primary signal for the amplification in β cells persistently depolarized by K\textsubscript{ATP} channel inactivation, such as that found in diabetes. They also demonstrate that a Gs-to-Gq signaling switch determines the differential efficacies of GLP-1 and GIP in improvement of glucose tolerance as well as the amplification of insulin response to glucose in the diabetic state. In addition, Gq-specific agonists are effective amplifiers of insulin secretion in persistently depolarized β cells. Although the mechanisms underlying the switch require detailed analyses by structural biology in
combination with site-directed mutagenesis and molecular docking simulation, the present findings provide important leads for the development of insulin secretion–based T2D therapies.

Methods

Additional details are provided in Supplemental Methods.

Animals. Mice were housed, 2 to 3 per cage, under specific pathogen–free conditions at 23 ± 2°C and 55% ± 10% relative humidity with a 12-hour light/12-hour dark cycle, and were freely provided with water and commercially obtained CE-2 diet (CLEA Japan Inc.). The numbers of animals studied per genotype are indicated for each experiment.

Generation of βKcnj11–/– mice. Kcnj11fl/+ mice were generated so as to have the Kncj11 gene flanked by 2 loxP sites (Supplemental Figure 1A). The targeting vector was constructed by inserting 2 loxP sites: one into the promoter region and the other into the 3′ untranslated region of the single-exon Kncj11 gene. The embryonic stem (ES) cells with homologous recombination were used to generate the mice carrying the loxP+Neo allele. Then, the Neo′ cassette of these mice was deleted, leading to the establishment of Kcnj11fl/+ mice.

βKcnj11–/– mice, β cell–specific Kcnj11–KO mice, were generated by crossing Kcnj11 fl/fl mice with RIP-Cre + mice (32) (a gift from Pedro L. Herrera, Department of Morphology, University of Geneva Medical School, Geneva, Switzerland), as described in Supplemental Figure 1A. All experiments were performed using age-matched control and βKcnj11–/– mice aged between 11 weeks and 19 weeks.

Generation of Kcnj11–/– β cell lines (Kcnj11–/– βCLs) by CRISPR/Cas9 system and cell culture. Kcnj11–/– β cell lines were generated from the parental MIN6-K8 β cell line, which was previously generated in our lab (69) by the CRISPR/Cas9 system as previously reported (45). In brief, MIN6-K8 cells were reverse transfected with a combination of the Cas9 D10A nickase expression vector and a pair of L/R-sgRNA vectors (0.133 μg/mL for each) using Lipofectamine 2000 transfection reagent according to the manufacturer’s instructions. After 48 hours of incubation, 400 μg/mL hygromycin B was added for selec-
tion. After 4 days of incubation, cells were replated to recover for 11 days. For clonal isolation, cells were serially diluted in 10 cm dishes to form single colonies, which were then manually hand-picked under microscopy and expanded. For sequencing, genomic DNA was extracted from each colony using SimplePrep Reagent for DNA (Takara Bio) according to the manufacturer’s instruction. Cas9 target regions were amplified by PCR, and the PCR products were subjected to agarose gel electrophoresis. The PCR products showing different lengths from the WT allele were cloned into the pMD20-T blunt vector (Takara Bio) and analyzed by Sanger sequencing using the 3100-Avant Genetic Analyzer (Applied Biosystems). Parental MIN6-K8 was used as controls. The cell lines were grown in high-glucose DMEM containing 10% heat-inactivated FBS and maintained in a humidified incubator with 95% air and 5% CO₂ at 37°C.

Glucose tolerance test. For all glucose tolerance tests (oGTT or i.p.GTT), mice were fasted for 6 hours. Basal blood glucose was sampled at approximately 15 minutes, and glucose was administered as an oral gavage or by i.p. injection at a dose of 1.5 g/kg body weight. Blood samples were obtained from the tail vein. For measurements of plasma insulin, GLP-1, and GIP, blood was collected in heparinized syringes and placed into a tube containing an inhibitor cocktail mixture of KRB 62436, EDTA, and aprotinin. Blood glucose levels were measured by the Antsense III Glucose Analyzer (Horiba), and plasma insulin, total GLP-1, total GIP, active GLP-1, and active GIP were determined by their respective ELISA kits.

Measurements of insulin secretion. For measurement of insulin secretion from mouse pancreatic islets, the islets were isolated from mice by collagenase digestion, as described previously (70), and cultured for 2 days, or as indicated in the Figure 5 and 6 legends. Insulin-secretion experiments from mouse islets and cell lines were performed as previously described (71). Insulin released and content was determined by homogeneous time-resolved fluorescence assay (HTTRF) using the Insulin UltraSensitive HTTRF Assay Kit (Cisbio). The amount of insulin secretion was normalized by islet insulin content. For measurement of insulin secretion from perfused pancreases, perfusion experiments were performed as previously described (28).

Briefly, overnight-fasted (16 hours) male mice 12 to 20 weeks of age were used. The perfusion protocol began with a 20-minute equilibration period with the same buffer used in the initial step shown in the figures. The flow rate of the perfusate was 1 mL/min. The insulin levels in the perfusate were measured by HTTRF using the Insulin UltraSensitive HTTRF Assay Kit (Cisbio). For measurement of insulin secretion from human islets, human islets were maintained in culture for up to 3 days in RPMI containing 5 or 16.7 mM glucose. Experiments were conducted using batches of 13 to 15 hand-picked and size-matched islets per tube (in triplicate). Following culture for 3 days, islets were washed twice in RPMI before preincubation in KRB containing 2 mg/mL BSA (S6003, Sigma-Aldrich) and 2.8 mM glucose for 1 hour at 37°C. Following this, islets were incubated in 0.3 mL KRB with 2 mg/mL BSA supplemented with various glucose concentrations or compounds for 1 hour. Insulin secretion was assayed using Meso Scale Discovery or Mercodia human insulin kits.

Measurements of glucagon secretion. Pancreatic islets were isolated and prepared as for insulin above, except that they were preincubated in KRB containing 16.7 mM glucose. Glucagon released in the incubation buffer and islet glucagon content was measured by the Mercodia Glucagon Elisa Kit.
Measurement of intracellular Ca\textsuperscript{2+} concentration in cell lines. Cells were loaded with 5 μM fura-2 AM (Dojindo) for 20 minutes in KRBBS with 2.8 mM glucose. Intracellular Ca\textsuperscript{2+} concentration was measured by a dual-excitation wavelength method (340/380 nm) with a fluorometer (Fluoroskan Ascent CF; Labsystems) in the presence of indicated reagents. Data were expressed as the ratio of the fluorescence emission at 340/380 nm after background subtraction.

Ca\textsuperscript{2+} imaging analysis in human islets. Islets were preincubated for 3 days in RPMI 1640 containing either 5.5 or 16.7 mM glucose. Before imaging, islets were loaded with 8 μM Fluo-4 AM (Thermo Fisher) at room temperature (21°C) for 90 minutes in imaging buffer consisting of 140 mM NaCl, 3.6 mM KCl, 0.5 mM MgSO\textsubscript{4}, 1.3 mM CaCl\textsubscript{2}, 10 mM HEPES (pH 7.4 with NaOH), 5 mM NaHCO\textsubscript{3}, and 0.5 mM NaH\textsubscript{2}PO\textsubscript{4} with either 5.5 mM or 16.7 mM glucose (reflecting the culture conditions). 1 mg/mL BSA, and 0.02% pluronic F-127 (Thermo Fisher). An islet was transferred to a poly-l-lysine–coated (MilliporeSigma) cover slip mounted in the imaging chamber (RC25, Warner Instruments) of a 2-photon microscope (TrimScope II Lavisin Biotec). Before time-lapse imaging, the islet was superfused for 20 minutes with imaging buffer (ES) heated to 34°C and containing 1 mM glucose. The titanium-sapphire laser (MaiTai, Spectra Physics) of the microscope was tuned to 820 nm, and images were acquired with a frame rate of 4 Hz.

IP1 assay. Cells were plated on 384-well plates and cultured as for cAMP measurement. Following 6 hours of culture in 5.6 mM glucose, the cells were washed 3 times and preincubated with buffer containing 146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl\textsubscript{2}, 1.0 mM CaCl\textsubscript{2}, 10.0 mM HEPES, 50 mM LiCl, and 2.8 mM glucose. The cells were then stimulated for 30 minutes in indicated stimuli. IP1 levels in the cells were measured by the IP-One HTRF Kit (Cisbio) according to the manufacturer’s instructions.

RNA extraction and quantitative RT-PCR. Total RNA from mouse pancreatic islets was isolated using the QIAAGEN RNA Extraction Kit per the manufacturer’s instructions. From this, cDNA was prepared using the ReverTra Ace qPCR RT Kit (Toyobo) according to the manufacturer’s instructions. TaqMan probes (Thermo Fisher Scientific) were used to quantify relative gene expression. The reference gene used was Gapdh. Probe details are described in Supplemental Table 4.

RNA-Seq. Detailed methods are described in Supplemental Methods. All original and processed RNA-Seq data were deposited in the NCBI’s Gene Expression Omnibus database (GEO GSE156917).

Protein assay. Cells were lysed in ice-cold buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitor cocktails and centrifuged for 20 minutes (13,000 g). Protein concentration was assessed by Pierce BCA protein assay.

Western blot analysis. Western blot analysis was performed as described previously (76) using anti-phosphoserine PKC substrates antibody (1:1000).

Statistics. Data were analyzed by GraphPad Prism, version 8.4.2, and are presented as mean ± SEM. The significance of differences between test groups was evaluated by 2-tailed unpaired Student’s t test or 2-way ANOVA followed by post hoc Tukey’s test or Dunnett’s test. P < 0.05 was considered statistically significant.

Study approval. All animal experiments were approved by the Committee on Animal Experimentation of Kobe University and Fukushima Medical University and carried out in accordance with the Guidelines for Animal Experimentation at the respective universities. For human islet experiments, islets were isolated in Oxford, Edmonton, and Uppsala. Islets from a total of 9 donors were used for these experiments with full approval and informed consent. Details of the donors are summarized in Supplemental Table 3.

Author contributions
S Seino conceived the project. S Seino and OSO contributed to the study design. OSO, NM, KS, HT, KM, TM, S Sakai, Y Maejima, QZ, HD, BC, CG, LK, and JT conducted in vivo, ex vivo, and in vitro experiments. HT, NY, PR, and S Seino supervised the work. OSO, HT, NY, KS, KM, QZ, HD, JT, Y Minami, PR, and S Seino were involved in data analyses and interpretation. OSO, PR, and S Seino wrote the manuscript with feedback from all other authors, including significant contributions from NM, KS, HT, NY, and TM.

Acknowledgments
We thank P.L. Hererra and J. Goedhart for providing us with RIP-Cre mice and the Gq FRET sensor, respectively. We also thank C. Carmean, T. Shibasaki, Y. Seino, T. Yada, and G. Bell for their insightful discussions. We are grateful to A. Kawabata and C. Seki for technical assistance and G. K. Honkawa for assistance in preparing the manuscript. This study was supported by Grant-in-Aid for Scientific Research from the Japan Society of the Promotion of Science, Japan to S Seino. (18H02864) and KS (17K09840). Work in the UK was supported by Diabetes UK (to QZ) and the Wellcome Trust (PR), and work in Sweden was supported by the Swedish Research council (to PR). OSO was supported by the Honjo International Scholarship Foundation, Japan, and a fellowship grant from Novo Nordisk, Denmark. NM was supported by a fellowship grant from Novo Nordisk, Denmark, and the Research Fellowship of Japan Society for the Promotion of Science Young Scientist DC1. The Department of Molecular and Metabolic Medicine is supported by MSD K.K. Novo Nordisk Pharma Ltd., Japan, Kowa Co. Ltd., and Taisho Pharmaceutical Holdings Co. Ltd.

Address correspondence to: Susumu Seino, Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Email: seino@med.kobe-u.ac.jp.

TM’s present address is: Department of Medical Physiology, Chiba University, Graduate School of Medicine, Chiba, Japan.
RESEARCH ARTICLE


